Novozymes A/S (NVZMY) Stock
Novozymes A/S

Company profile
Novozymes A/S reported revenue of 4.16 billion EUR for fiscal year 2025, up 8.5% from fiscal year 2024, and net income of 583.60 million EUR. That is a net profit margin of 14.0% for fiscal year 2025. In Q2 2026 (the quarter ended June 30, 2026) revenue was 1.12 billion EUR, up 9.6% from a year before. In Q2 2026 it reported net income of 171.70 million EUR, against net income of 136.80 million EUR a year earlier. Our analysis of its filings shows revenue growing from 2.40 billion EUR in fiscal year 2023 to 4.16 billion EUR in fiscal year 2025, 31.6% a year on average. Novozymes A/S reports about 10,933 full-time employees.
What stands out
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.
Leadership
- Ester Baiget — President & CEO, 54
- Tue Micheelsen — President of Novonesis North America & Head of Global Consumer Health
- Rainer Lehmann — Executive VP & CFO, 50
- Anders Lund — Chief Operating Officer, 52
- Claus Crone Fuglsang — Chief Scientific Officer, 57
In the news
- KROS or NVZMY: Which Is the Better Value Stock Right Now?
- Food Enzymes Market Competitive Landscape Report 2025: Players Analysis by Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue Forecast
- Novozymes (CPSE:NSIS B): Assessing Valuation After Upward Sales Growth Guidance and Improved Q3 Results
- Why Novozymes (CPSE:NSIS B) Is Up 11.4% After Raising Guidance and Reporting Strong YTD Results
How much revenue does Novozymes A/S make?
Novozymes A/S reported 4.16 billion EUR in revenue for fiscal year 2025, up 8.5% from 3.83 billion EUR in fiscal year 2024. In Q2 2026 revenue was 1.12 billion EUR.
How has Novozymes A/S's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 2.01 billion EUR; FY2022, 2.36 billion EUR; FY2023, 2.40 billion EUR; FY2024, 3.83 billion EUR; FY2025, 4.16 billion EUR.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Novozymes A/S (NVZMY)”, data as of Jun 30, 2026, https://dataporium.tech/stocks/NVZMY